SAN DIEGO, July 23, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, invites investors and the general public to its Annual Shareholder Meeting at 9:00 AM PT/12:00 PM ET on Friday, July 31, 2015. The meeting will be held at the following location: 10996 Torreyana Road, Lighthouse Room, San Diego, California 92121.
A live webcast of the meeting will also be available. Please use the following link to register for the meeting: https://engage.vevent.com/rt/oncosecmedicalincorporated~073115. An archived version of the webcast will be available for 90 days on OncoSec's website: www.oncosec.com.
To access the Notice of Annual Meeting of Stockholders and Proxy Statement, which describe the formal business to be conducted at the meeting, please click here.
About OncoSec Medical Incorporated
OncoSec is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ IL-12 have demonstrated an acceptable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma and squamous cell carcinoma of the head and neck. In addition to ImmunoPulse™ IL-12, the company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
SOURCE OncoSec Medical Inc.